Clinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker.

The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analysed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-alpha-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and beta2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to US Provisional Application No. 60/842,980 filed September 8, 2006, the disclosure of which is incorporated herein by reference in its entirety.

FIELD OF INVENTION

The present application relates generally to methods for diagnosing hepatic fibrosis using a panel of antibodies targeted against a novel panel of fibrosis biomarkers. These novel proteins may also serve as biomarkers for hepatitis and hepatocellular carcinoma (HCC) as well as drug targets for hepatic scarring and HCC.

BACKGROUND OF THE INVENTION

Hepatic fibrosis. Hepatic fibrosis (liver fibrosis) is a wound healing response characterised by the excessive accumulation of scar tissue (i.e. extracellular matrix) in the liver. Normal structural elements of tissues are replaced with excessive amounts of non-functional scar tissue. Needle liver biopsy is the primary tool for the diagnosis and assessment of fibrosis yet there are a number of well-documented limitations and disadvantages to this technique including patient discomfort, pain, bleeding, and death in rare cases. Furthermore, a biopsy can be unreliable if fibrosis is not homogenous throughout the liver. Hepatic fibrosis can be caused by various factors including alcohol and viruses.

Cirrhosis. Hepatic cirrhosis is the most severe form of liver scarring and, unlike hepatic fibrosis, is generally considered to be irreversible and nodular. Cirrhosis is the cause of over 6000 deaths every year in the UK and approximately 27,000 in the USA, making it the ninth leading cause of death (MacSween et al., (2002), Pathology of the Liver, 4th Edition, Churchill Livingstone). Cirrhosis is a major risk factor for HCC and, at this stage of liver cancer, the only curative approach is liver transplantation. In the case of virally induced liver cancer, hepatic scarring and HCC can recur after transplantation. It is imperative to diagnose fibrosis in the early stages of reversible liver scarring so that irreversible cirrhosis can be prevented.

Hepatitis C virus. Approximately 170 million people worldwide, i.e. 3 % of the world’s population (see e.g. WHO, J. Viral. Hepat. 1999; 6: 35-47), and approximately 4 million people in the United States are infected with Hepatitis C virus (HCV, HepC). HCV is of the leading causes of hepatic fibrosis and cirrhosis. About 80 % of individuals acutely infected with HCV become chronically infected. Hence, HCV is a major cause of chronic hepatitis. Once chronically infected, the virus is almost never cleared without treatment. In rare cases, HCV infection causes clinically acute disease and even liver failure. Chronic HCV infection can vary dramatically between individuals, where some will have clinically insignificant or minimal liver disease and never develop complications and others will have clinically apparent chronic hepatitis and may go on to develop fibrosis and cirrhosis. About 20 % of individuals with HCV who do develop cirrhosis will develop end-stage liver disease and have an increased risk of developing primary liver cancer.

SUMMARY OF THE INVENTION

The present invention provides methods for the detection of fibrosis.

In one embodiment, the invention provides a method of detecting fibrosis, comprising: (a) determining the level of a HF-ASSOCIATED polypeptide in a biological sample obtained from a patient; and (b) comparing said level (a) to a control level of said HF-ASSOCIATED polypeptide in order to determine a positive or negative diagnosis of said fibrosis. These biomarkers may be applied to any disease which displays fibrosis such as hepatic fibrosis, renal fibrosis, cardiac fibrosis, skin fibrosis, pancreatic fibrosis etc. but in specific embodiments the fibrosis is hepatic fibrosis. Preferably, the polypeptide is selected from the group consisting of: inter-α-trypsin inhibitor heavy chain H4 fragments, α1 antichymotrypsin, apolipoprotein L1 (Apo L1), prealbumin, albumin, isoforms of CD5 antigen like protein (CD5L), β2 glycoprotein I (β2GPI), α2 macroglobulin (a2M) and immunoglobulin components, α1, α2 and β chains of haptoglobin, complement components (C3, C4 and factor H-related protein 1), adiponectin, ApoE, prothrombin, clusterin, and angiotensinogen. In other embodiments, the fibrosis includes differential regulation of HF-ASSOCIATED polypeptides. In other embodiments, the sample is taken from blood serum or plasma.

In another embodiment, the current invention provides a method for detecting a HF-ASSOCIATED polypeptide comprising: a) isolating a biological sample from a patient with fibrosis, b) isolating a biological sample from a patient without fibrosis, c) analyzing the samples from a) and b) using 2D-PAGE, and d) comparing the 2D-PAGE results to identify polypeptides with differential expression between patients with and without fibrosis.
a) determining the level of at least one HF-ASSOCIATED polypeptide in a biological sample obtained from a patient; and b) comparing said level of HF-ASSOCIATED polypeptides in said patient biological sample to the predetermined level of said HF-ASSOCIATED polypeptides in a population of patients ranging from no fibrosis to cirrhosis.

[0011] In another embodiment, the current invention provides a kit useful for the prognosis of fibrosis, comprising a HF-ASSOCIATED agent wherein the agent specifically detects HF-ASSOCIATED polypeptides. In specific embodiments, the agent is an antibody or functional equivalent thereof that binds HF-ASSOCIATED polypeptides. These antibodies may be used to perform an ELISA assay. The kit may further comprise at least one target specifically for detecting another gene or gene product useful as a prognostic indicator.

[0012] In another embodiment, the current invention provides a method of determining the prognosis of fibrosis, comprising: (a) determining the level of a HF-ASSOCIATED polypeptide in a biological sample obtained from a patient; and (b) comparing said level of (a) to a control level of said HF-ASSOCIATED polypeptide in order to determine a positive or negative diagnosis of said fibrosis.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013] FIG. 1 to 4 These figures show the changes observed in expression of the main novel biomarkers. Each image shows a magnified region of the 2D-PAGE gel with the relative position of the identified protein circled. Representative serum gel images are shown for healthy individuals and patients with cirrhosis.

[0014] FIG. 1 CD5 antigen-like protein is shown to be absent in normal serum but present in serum from cirrhotic patients.

[0015] FIG. 2 Apolipoprotein L1 is shown to be present in normal serum but absent in serum from cirrhotic patients.

[0016] FIG. 3 Inter-α-trypsin inhibitor heavy chain H4. This inhibitor was found to be cleaved into 35 and 70 kDa fragments in serum samples from normal individuals. Serum from cirrhosis patients showed absence of the 35 kDa fragment and decreased expression of the 70 kDa fragment suggesting decreased cleavage of this protein.

[0017] FIG. 4 - β2 glycoprotein I is shown to be absent in normal serum but present in serum from cirrhotic patients.

[0018] FIG. 5 This figure demonstrates that cleavage of α2 macroglobulin increases with fibrosis. Images shown are magnified images (as in Figures 1-4) but shows serum spot profiles from healthy individuals, patients with mild fibrosis, moderate fibrosis and cirrhosis. U shows uncleaved α2 macroglobulin, H shows the heavy chain from cleaved α2 macroglobulin and L shows the light chain from cleaved α2 macroglobulin.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The following description outlines the invention summarized above. The invention, however, is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described and as such may vary. Likewise, the terminology used herein describes particular embodiments only, and is not intended to limit the scope of the invention.

[0020] The inventors have discovered that, various proteins are differentially expressed in human serum samples of HCV-induced fibrosis/cirrhosis patients when compared with healthy individuals. This discovery was achieved by comparing these serum samples using a technique that separates proteins in two dimensions on a gel matrix to give discrete protein spots.

[0021] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the relevant art.

[0022] All publications and patents mentioned herein are hereby incorporated herein by reference for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications which might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

a. Definitions

[0023] For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below.

[0024] The singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

[0025] "β2GPI" refers to β2 glycoprotein I.

[0026] "2D-PAGE" refers to two dimensional polyacrylamide gel electrophoresis.

[0027] "a2M" refers to α2 macroglobulin.

[0028] "ABTS" refers to 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid).

The phenomena can vary with the type of fibrosis, but the fibrosis phenotype is generally identified by abnormalities in the expression patterns of a gene. A determination as to whether a subject is presently affected by a disease or disorder, a prognosis of a subject characteristic of normal or diseased conditions. Diagnosis and diagnosing generally includes a determination of a subject's susceptibility to a disease or disorder, a determination as to whether a subject is presently affected by a disease or disorder, a prognosis of a subject affected by a disease or disorder (e.g., identification of pre-metastatic or metastatic cancerous states or fibrosis), and theranetics (e.g., monitoring a subject's condition to provide information as to the effect or efficacy of therapy).

Differential expression refers to both quantitative as well as qualitative differences in the temporal and tissue expression patterns of a gene. For example, a differentially expressed gene may have its expression activated or completely inactivated in normal versus disease conditions. Such a qualitatively regulated gene may exhibit an expression pattern within a given tissue, cell type, or in the serum/plasma of the subject that is detectable in either control or disease conditions, or detectable in both but with different expression. "Differentially expressed protein," as used herein, refers to an amino acid sequence that uniquely identifies a differentially expressed protein so that detection of the differentially expressed protein in a sample is correlated with the presence of a differentially expressed protein in a sample.

Expression generally refers to the process by which a polynucleotide sequence undergoes successful transcription and translation such that detectable levels of the amino acid sequence or protein are expressed. In certain contexts herein, expression refers to the production of mRNA. In other contexts, expression refers to the production of protein or fragments thereof. The fragments may be produced via enzymatic cleavage or biological processes characteristic of normal or diseased conditions.

An "expression product" or "gene product" is a biomolecule, such as a protein or mRNA, that is produced when
a gene in an organism is transcribed or translated or post-translationally modified.

A "fragment of a protein" refers to a portion of a protein. For example, fragments of proteins may comprise polypeptides obtained by digesting full-length protein isolated from cultured cells. In one embodiment, a protein fragment comprises at least about 6 amino acids. In another embodiment, the fragment comprises at least about 10 amino acids.

In yet another embodiment, the protein fragment comprises at least about 16 amino acids.

The term "functional equivalent" refers to a protein that possesses functional or structural characteristics that are substantially similar to all or part of the native HF-ASSOCIATED protein. The term "functional equivalent" is intended to include the "fragments," "mutants," "derivatives," "alleles," "hybrids," "variants," "analogs," or "chemical derivatives" of native HF-ASSOCIATED proteins.

In the context of this application, the term "homology," as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target polynucleotide; it is referred to using the functional term "substantially homologous."

The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

"Individual," "subject," "host," and "patient," used interchangeably herein, refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired. In one preferred embodiment, the individual, subject, host, or patient is a human. Other subjects may include, but are not limited to, cattle, horses, dogs, cats, guinea pigs, rabbits, rats, primates, woodchucks, ducks, and mice.

"Isolated" refers to a polynucleotide, a polypeptide, an immunoglobulin, or a host cell that is in an environment different from that in which the polynucleotide, the polypeptide, the immunoglobulin, or the host cell naturally occurs.

"Label" refers to agents that are capable of providing a detectable signal, either directly or through interaction with one or more additional members of a signal producing system. Labels that are directly detectable and may find use in the invention include fluorescent labels. Specific fluorophores include fluorescein, rhodamine, BODIPY, cyanine dyes and the like. The invention also contemplates the use of radioactive isotopes, such as 35S, 32P, 3H, and the like as labels. Colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypolyethylene, latex) beads may also be utilized. See, e.g., U.S. Patent Nos. 4,366,241; 4,277,437; 4,275,149; 3,996,345; 3,939,350; 3,850,752; and 3,817,837.

The term "normal physiological conditions" means conditions that are typical inside a living organism or a cell. Although some organs or organisms provide extreme conditions, the intra-organismal and intra-cellular environment...
"Polynucleotide" and "nucleic acid," used interchangeably herein, refer to polymeric forms of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, these terms include, but are not limited to, single-, double-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. These terms further include, but are not limited to, mRNA or cDNA that comprise intronic sequences. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. Alternatively, the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphorodiamidites and thus can be an oligodeoxynucleoside phosphoramidate or a mixed phosphoramidate-phosphodiester oligomer. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracil, other sugars, and linking groups such as fluororibose and thioate, and nucleotide branches. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support. The term "polynucleotide" also encompasses peptidic nucleic acids. Polynucleotides may further comprise genomic DNA, cDNA, or DNA-RNA hybrids.

"Polypeptide" and "protein," used interchangeably herein, refer to a polymeric form of amino acids of any length, which may include translated, untranslated, chemically modified, biochemically modified, and derivatized amino acids. A polypeptide or protein may be naturally occurring, recombinant, or synthetic, or any combination of these. Moreover, a polypeptide or protein may comprise a fragment of a naturally occurring protein or peptide. A polypeptide or protein may be a single molecule or may be a multi-molecular complex. In addition, such polypeptides or proteins may have modified peptide backbones. The terms include fusion proteins, including fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues, immunologically tagged proteins, and the like.

"Predisposition" to a disease or disorder refers to an individual's susceptibility to such disease or disorder. Individuals who are susceptible are statistically more likely to have cancer or fibrosis, for example, as compared to normal/wild type individuals.

The terms "prognosis" and "prognose" refer to the act or art of foretelling the course of a disease. Additionally, the terms refer to the prospect of survival and recovery from a disease as anticipated from the usual course of that disease or indicated by special features of the individual case. Further, the terms refer to the act or art of identifying a disease from its signs and symptoms.

The terms "prognostic indicator" or "indicator" refer to anything that may serve as, or relate to, a ground or basis for a prognosis. These terms further refer to any grounds or basis of a differential diagnosis, including the results of testing and characterization of gene expression as described herein, and the distinguishing of a disease or condition from others presenting similar symptoms. Additionally, the terms "indicator" or "prognostic indicator" refer to any grounds or basis, including the results of testing and characterization of gene expression as described herein, which may be used to distinguish the probable course of a malignant disease.

"Protein-capture agent" refers to a molecule or a multi-molecular complex that can bind a protein to itself. In one embodiment, protein-capture agents bind their binding partners in a substantially specific manner. In one embodiment, protein-capture agents may exhibit a dissociation constant (KD) of less than about 10^-6. The protein-capture agent may comprise a biomolecule such as a protein or a polynucleotide. The biomolecule may further comprise a naturally occurring, recombinant, or synthetic biomolecule. Examples of protein-capture agents include immunoglobulins, antigens, receptors, or other proteins, or portions or fragments thereof. Furthermore, protein-capture agents are understood not to be limited to agents that only interact with their binding partners through noncovalent interactions. Rather, protein-capture agents may also become covalently attached to the proteins with which they bind. For example, the protein-capture agent may be photocrosslinked to its binding partner following binding.

"Sequence Identity" refers to a degree of similarity or complementarity. There may be partial identity or complete identity. A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target polynucleotide; it is referred to using the functional term "substantially identical." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially identical sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely identical sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a
second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

[0073] Another way of viewing sequence identity in the context to two nucleic acid or polypeptide sequences includes reference to residues in the two sequences that are the same when aligned for maximum correspondence over a specified region. As used herein, percentage of sequence identity means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

[0074] "Stringent conditions" refers to conditions under which a probe may hybridize to its target polynucleotide sequence, but to no other sequences. Stringent conditions are sequence-dependent (e.g., longer sequences hybridize specifically at higher temperatures). Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH, and polynucleotide concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to about 1.0 M sodium ion concentration (or other salts) at about pH 7.0 to about pH 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

[0075] "Substantially purified" refers to a compound that is removed from its natural environment and is at least about 60% free, at least about 65% free, at least about 70% free, at least about 75% free, at least about 80% free, at least about 83% free, at least about 85% free, at least about 88% free, at least about 90% free, at least about 91% free, at least about 92% free, at least about 93% free, at least about 94% free, at least about 95% free, at least about 96% free, at least about 97% free, at least about 98% free, at least about 99% free, or at least about 99.9% free from other components with which it is naturally associated.

[0076] A "target protein" refers to a polypeptide, often derived from a biological sample, to which a protein-capture agent specifically hybridizes or binds. It is either the presence or absence of the target protein that is to be detected, or the amount of the target protein that is to be quantified. The target protein has a structure that is recognized by the corresponding protein-capture agent directed to the target. The target protein or amino acid may also refer to the specific substructure of a larger protein to which the protein-capture agent is directed or to the overall structure (e.g., gene or mRNA) whose expression level it is desired to detect.

[0077] The terms "treatment," "treating," "treat," and the like refer to obtaining a desired pharmacological and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete stabilization or cure for a disease and/or adverse effect attributable to the disease. "Treatment" covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease or symptom from occurring in a subject which may be predisposed to the disease or symptom but has not yet been diagnosed as having it; (b) inhibiting the disease symptom, i.e., arresting its development; or (c) relieving the disease symptom, i.e., causing regression of the disease or symptom.

b. HF-ASSOCIATED Polypeptides

[0078] In one aspect, the invention relates to "HF-ASSOCIATED polypeptides," which includes polypeptides whose differential expression is associated with hepatic fibrosis. HF-ASSOCIATED polypeptides also include variants of the naturally occurring proteins, where such variants are identical or substantially similar to the naturally occurring protein. In general, variant polypeptides have a sequence that has at least about 80%, usually at least about 90%, and more usually at least about 98% sequence identity with a HF-ASSOCIATED polypeptide described herein, as measured by BLAST. Variant polypeptides can be naturally or non-naturally glycosylated.

[0079] In general, variants of the HF-ASSOCIATED polypeptides described herein have a sequence identity greater than at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 83%, at least about 85%, at least about 88%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% or may be greater than at least about 99.99% as determined by methods well known in the art, such as BLAST.

[0080] In one embodiment, a variant HF-ASSOCIATED polypeptide may be a mutant polypeptide. The mutations in the HF-ASSOCIATED polypeptide may result from, but are not limited to, amino acid substitutions, additions or deletions. The amino acid substitutions may be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids. In general, conservative amino acid substitutions are those that preserve the general charge, hydrophobicity, hydrophilicity, and/or steric bulk of the amino acid substituted.
In some mutant HF-ASSOCIATED polypeptides, amino acids may be substituted to alter a phosphorylation site or an acetylation site.

Importantly, variant polypeptides may be designed so as to retain or have enhanced biological activity of a particular region of the protein (e.g., a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). Selection of amino acid alterations for production of variants may be based upon the accessibility (interior vs. exterior) of the amino acid, the thermostability of the variant polypeptide, desired glycosylation sites, desired disulfide bridges, desired metal binding sites, and desired substitutions within proline loops. Cysteine-depleted muteins can be produced as disclosed in USPN 4,959,314.

Variants also include fragments of the HF-ASSOCIATED polypeptides disclosed herein, particularly biologically active fragments and fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 aa to at least about 15 aa in length, usually at least about 50 aa in length, and can be as long as 300 aa in length or longer. The protein variants described herein are encoded by polynucleotides that are within the scope of the invention.

HF-ASSOCIATED polypeptides of the invention are provided in a non-naturally occurring environment, e.g., are separated from their naturally occurring environment. In certain embodiments, HF-ASSOCIATED protein is present in a substantially purified form.

c. HF-ASSOCIATED Agents: Modulators and Binding Partners

In another aspect, the invention provides a "HF-ASSOCIATED agent," which refers to a class of molecules that consists of "HF-ASSOCIATED polypeptide binding partners."

HF-ASSOCIATED polypeptide binding partners are molecules that bind to HF-ASSOCIATED polypeptides. Exemplary polypeptide binding partners are immunoglobulins. Binding partners may, but need not, modulate a HF-ASSOCIATED polypeptide's biological activity.

d. Immunoglobulins

HF-ASSOCIATED agents used to identify HF-ASSOCIATED proteins include immunoglobulins and functional equivalents of immunoglobulins that specifically bind to HF-ASSOCIATED polypeptides. The terms "immunoglobulin" and "antibody" are used interchangeably and in their broadest sense herein. Thus, they encompass intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity. In one embodiment, the subject immunoglobulins comprise at least one human constant domain. In another embodiment, the HF-ASSOCIATED agent immunoglobulins comprise a constant domain that exhibits at least about 90-95% sequence identity with a human constant domain and yet retains human effector function. An immunoglobulin HF-ASSOCIATED agent or functional equivalent thereof may be human, chimeric, humanized, murine, CDR-grafted, phage-displayed, bacteria-displayed, yeast-displayed, transgenic-mouse produced, mutagenized, and randomized.

i. Antibodies Generally

The terms "antibody" and "immunoglobulin" cover fully assembled antibodies and antibody fragments that can bind antigen (e.g., Fab', F'(ab)2, Fv, single chain antibodies, diabodies), including recombinant antibodies and antibody fragments. Preferably, the immunoglobulins or antibodies are chimeric, human, or humanized.

The variable domains of the heavy and light chain recognize or bind to a particular epitope of a cognate antigen. The term "epitope" is used to refer to the specific binding sites or antigenic determinant on an antigen that the variable end of the immunoglobulin binds. Epitopes can be linear, i.e., be composed of a sequence of amino acid residues found in the primary HF-ASSOCIATED sequence. Epitopes also can be conformational, such that an immunoglobulin recognizes a 3-D structure found on a folded HF-ASSOCIATED molecule. Epitopes can also be a combination of linear and conformational elements. Further, carbohydrate portions of a molecule, as expressed by the target bearing tumor cells can also be epitopes.

Immunoglobulins are said to be "specifically binding" if: 1) they exhibit a threshold level of binding activity, and/or 2) they do not significantly cross-react with known related polypeptide molecules. The binding affinity of an immunoglobulin can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, Ann. NY Acad. Sci. 51: 660-672, 1949). In some embodiments, the immunoglobulins of the present invention bind to HF-ASSOCIATED at least 10³, more preferably at least 10⁴, more preferably at least 10⁵, and even more preferably at least 10⁶ fold higher than to other proteins.
ii. Polyclonal and Monoclonal Antibodies

[0091] Immunoglobulins of the invention may be polyclonal or monoclonal, and may be produced by any of the well known methods in this art.

[0092] Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc), intraperitoneal (ip) or intramuscular (im) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized. In addition, aggregating agents such as alum and others are suitably used to enhance the immune response.

[0093] The term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants, each monoclonal antibody is directed against a single determinant on the antigen.

[0094] In addition to their specificity, monoclonal antibodies are advantageous in that they may be synthesized while uncontaminated by other immunoglobulins. For example, monoclonal antibodies may be produced by the hybridoma method or by recombinant DNA methods. Monoclonal antibody HF-ASSOCIATED agents also may be isolated from phage antibody libraries.

iii. Chimeric and Humanized Antibodies

[0095] HF-ASSOCIATED polypeptide-binding immunoglobulins or antibodies can be "chimeric" in the sense that a variable region can come from a one species, such as a rodent, and the constant region can be from a second species, such as a human.

[0096] "Humanized" forms of non-human HF-ASSOCIATED protein-binding antibodies are chimeric antibodies that contain minimal sequence derived from a non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody.

[0097] In general, the humanized antibody may comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. In one embodiment, humanized antibodies comprise a humanized FR that exhibits at least 65% sequence identity with an acceptor (non-human) FR, e.g., murine FR. The humanized antibody also may comprise at least a portion of an immunoglobulin constant region (Fc), particularly a human immunoglobulin.

[0098] Methods for humanizing non-human antibodies have been described in the art. Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source, which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization may be essentially performed by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity.

[0099] Other methods generally involve conferring donor CDR binding affinity onto an antibody acceptor variable region framework. One method involves simultaneously grafting and optimizing the binding affinity of a variable region binding fragment. Another method relates to optimizing the binding affinity of an antibody variable region.

iv. Antibody Fragments

[0100] "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen-binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')², Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.

[0101] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment. The Fab fragments also contain the constant domain of the light chain and the first constant domain (CH1) of the heavy chain.

[0102] Pepsin treatment yields an F(ab')² fragment that has two antigen-binding sites and is still capable of crosslinking antigen. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy
chain CHI domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear at least one free thiol group. F(ab')² antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are well known in the art.

**[0103]** *"Fv"* is the minimum antibody fragment that contains a complete antigen-recognition and antigen-binding site. This region consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six hypervariable regions confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

**[0104]** *Single-chain Fv* or *"scFv"* antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. The Fv polypeptide may further comprise a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. See PLUCKTHUN, 113 THE PHARMACOLOGY OF MONOCLONAL ANTIBODIES 269-315 (Rosenburg and Moore eds. 1994). See also WO 93/16185; U.S. Patent Nos. 5,587,458 and 5,571,894.

**[0105]** Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies. However, these fragments may now be produced directly by recombinant host cells.

**v. Conjugation and Labeling**

**[0106]** Anti-HF-ASSOCIATED protein antibodies may be administered in their "naked" or unconjugated form, or may have other agents conjugated to them.

**[0107]** For examples the antibodies may be in detectably labeled form. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, etc.) fluorescent labels (such as FITC or rhodamine, etc.), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well known in the art.

**vi. Bispecific Antibodies**

**[0108]** Bispecific antibodies of the invention are small antibody fragments with two antigen-binding sites. Each fragment comprises a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen binding sites.

**[0109]** Methods for making bispecific antibodies are well known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities.

**[0110]** In another approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) may be fused to immunoglobulin constant domain sequences. Specifically, the variable domains are fused with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. In one embodiment, the fusion protein comprises the first heavy-chain constant region (CHI) because it contains the site necessary for light chain binding. Polynucleotides encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, may be inserted into separate expression vectors and co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

**[0111]** Bispecific antibodies also have been produced using leucine zippers and single-chain Fv (sFv) dimers.

**e. Diagnosis, Prognosis, and Assessment of Fibrosis Therapy**

**[0112]** In another aspect, therefore, the invention provides methods for using the HF-ASSOCIATED polypeptides described herein to diagnose and prognose fibrosis. In specific non-limiting embodiments, the methods are useful for detecting HF-ASSOCIATED polypeptides in cells or serum/plasma, facilitating diagnosis of fibrosis and the severity of a fibrosis in a subject, facilitating a determination of the prognosis of a subject, determining the susceptibility to fibrosis in a subject, and assessing the responsiveness of the subject to therapy (e.g., by providing a measure of therapeutic effect through, for example, assessing tumor burden during or following a chemotherapeutic regimen). Such methods
may involve detection of levels of HF-ASSOCIATED polypeptides in a patient biological sample, e.g., serum/plasma or a suspected or prospective fibrotic tissue or cell. The detection methods of the invention may be conducted in vitro or in vivo, on isolated cells, or in whole tissues or a bodily fluid, e.g., blood, plasma, serum, urine, and the like. In one embodiment, the HF-ASSOCIATED polypeptides may be used to detect and assess fibrosis. These biomarkers may be applied to any disease which displays fibrosis such as hepatic fibrosis, renal fibrosis, cardiac fibrosis, skin fibrosis, pancreatic fibrosis etc. but more preferably, the fibrosis is hepatic fibrosis.

f. Detecting a HF-ASSOCIATED Polypeptide

[0113] Methods are provided for detecting a HF-ASSOCIATED polypeptide in serum. Any of a variety of known methods may be used for detection, including, but not limited to, immunoassay, using antibody specific for the encoded polypeptide, e.g., by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and the like; and functional assays for the encoded polypeptide, e.g., biological activity.

[0114] As will be readily apparent to the ordinarily skilled artisan upon reading the present specification, the detection methods and other methods described herein may be readily varied. Such variations are within the intended scope of the invention. For example, in the above detection scheme, the probe for use in detection may be immobilized on a solid support, and the test sample contacted with the immobilized probe. Binding of the test sample to the probe may then be detected in a variety of ways, e.g., by detecting a detectable label bound to the test sample to facilitate detection of test sample-immobilized probe complexes.

[0115] The invention further provides methods for detecting the presence of and/or measuring a level of HF-ASSOCIATED polypeptide in a biological sample, using an antibody specific for HF-ASSOCIATED polypeptides. Specifically, the method for detecting the presence of HF-ASSOCIATED polypeptides in a biological sample may comprise the step of contacting the sample with a monoclonal antibody and detecting the binding of the antibody with the HF-ASSOCIATED polypeptide in the sample. More specifically, the antibody may be labeled so as to produce a detectable signal using compounds including, but not limited to, a radiolabel, an enzyme, a chromophore and a fluorophore.

[0116] Detection of specific binding of an antibody specific for HF-ASSOCIATED polypeptide, or a functional equivalent thereof, when compared to a suitable control, is an indication that HF-ASSOCIATED polypeptides are present in the sample. Suitable controls include a sample known not to contain HF-ASSOCIATED polypeptides and a sample contacted with an antibody not specific for the encoded polypeptide, e.g., an anti-idiotype antibody. A variety of methods to detect specific antibody-antigen interactions are known in the art and may be used in the method, including, but not limited to, standard immunohistological methods, immunoprecipitation, an enzyme immunoassay, and a radioimmunoassay. In general, the specific antibody will be detectably labeled, either directly or indirectly. Direct labels include radioisotopes; enzymes whose products are detectable (e.g., luciferase, 3-galactosidase, and the like); fluorescent labels (e.g., fluorescein isothiocyanate, rhodamine, phycocerythrin, and the like); fluorescence emitting metals (e.g., 112Eu, or others of the lanthanide series, attached to the antibody through metal chelating groups such as EDTA); chemiluminescent compounds (e.g., luminol, isoluminol, acridinium salts, and the like); bioluminescent compounds (e.g., luciferin, aequorin (green fluorescent protein), and the like). The antibody may be attached (coupled) to an insoluble support, such as a polystyrene plate or a bead. Indirect labels include second antibodies specific for antibodies specific for the encoded polypeptide (“first specific antibody”), wherein the second antibody is labeled as described above; and members of specific binding pairs, e.g., biotin-avidin, and the like. The biological sample may be brought into contact with and immobilized on a solid support or carrier, such as nitrocellulose, that is capable of immobilizing cells, cell particles, or soluble proteins. The support may then be washed with suitable buffers, followed by contacting with a detectably-labeled first specific antibody. Detection methods are known in the art and will be chosen as appropriate to the signal emitted by the detectable label. Detection is generally accomplished in comparison to suitable controls and to appropriate standards.

g. Kits

[0117] The detection methods may be provided as part of a kit. Thus, the invention further provides kits for detecting the presence and/or a level of a HF-ASSOCIATED polypeptide in a biological sample. Procedures using these kits may be performed by clinical laboratories, experimental laboratories, medical practitioners, or private individuals. The kits of the invention for detecting a HF-ASSOCIATED polypeptide that is differentially expressed during fibrosis. The kit may provide additional components that are useful in procedures, including, but not limited to, buffers, developing reagents, labels, reacting surfaces, means for detection, control samples, standards, instructions, and interpretive information.
Examples

Differentially Expressed Proteins Established When Comparing Serum From Normal Healthy Individuals With Fibrosis/Cirrhosis Patients

[0118] The inventors have discovered that various proteins are differentially expressed in human serum samples of HCV-induced fibrosis/cirrhosis patients when compared with healthy individuals - Gangadharan et al., (2007), Clin. Chem., 53. This discovery was achieved by comparing these serum samples using two dimensional polyacrylamide gel electrophoresis (2D-PAGE), a technique that separates proteins in two dimensions on a gel matrix to give discrete protein spots. This is the first use of a 2D-PAGE approach to identify serum biomarkers for fibrosis.

Example 1

Two dimensional polyacrylamide gel electrophoresis (2D-PAGE)

[0119] To identify biomarkers for different stages of HCV-induced fibrosis, serum samples of healthy individuals and HCV-induced fibrosis/cirrhosis patients (15 individuals) were analysed in a 2D-PAGE-based proteomics study. 500 µg of serum proteins were separated by charge using a pH 3-10 non-linear gradient in the first dimension of the gel and by molecular weight (size) in the second dimension. Electrophoresis, fluorescent staining and scanning of gels were performed as described by Gangadharan et al., (2007), Clin. Chem., 53.

Example 2

Differential Image Analysis and protein identification

[0120] The two dimensional array of spots generated were compared between normal and fibrosis/cirrhosis serum samples by computer-aided image analysis. Scanned images of all 2D-PAGE gels were analysed by computer-aided image analysis as described by Gangadharan et al., (2007), Clin. Chem., 53. Differentially expressed changes that were greater than or equal to 2-fold different were considered to be significant. A total of 53 differentially expressed features were excised, digested with trypsin, and analysed by mass spectrometry.

Example 3

Identification of Human Serum Biomarkers for Hepatic Fibrosis Due to Cirrhosis

[0121] Differential image analysis revealed initial evidence for potential serum biomarkers. See Figures 1-5. The most prominent changes were observed when comparing serum samples from cirrhotic patients with healthy controls. This analysis showed that expression of inter-α-trypsin inhibitor heavy chain H4 fragments (ITIH4), α1 antichymotrypsin, apolipoprotein L1 (Apo L1), prealbunin and albumin was decreased in cirrhotic serum, whereas expression of CD5 antigen like protein (CD5L) and β2 glycoprotein I (β2GPI) increased. In general, α2 macroglobulin (a2M) and immunoglobulin components increased with hepatic fibrosis whereas α1, α2 and β chains of haptoglobin and complement components (C3, C4 and factor H-related protein 1) decreased.

<table>
<thead>
<tr>
<th>Patients with Cirrhosis</th>
<th>Increase</th>
<th>Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>inter-α-trypsin inhibitor heavy chain H4 fragments</td>
<td>CD5 antigen like protein (CD5L)</td>
<td></td>
</tr>
<tr>
<td>α1 antichymotrypsin</td>
<td>β2 glycoprotein I (β2GPI)</td>
<td></td>
</tr>
<tr>
<td>apolipoprotein L1 (Apo L1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>prealbumin and albumin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>α1, α2 and β chains of haptoglobin and complement components (C3, C4 and factor H-related protein 1)</td>
<td>α2 macroglobulin (a2M) immunoglobulin components</td>
<td></td>
</tr>
</tbody>
</table>
Identification of Human Serum Biomarkers for Hepatic Fibrosis Due to HCV-Induced Fibrosis

[0122] Novel proteins associated with HCV-induced fibrosis were identified from the differential image analysis. Table 1 provides a summary of selected differentially expressed proteins that have been classified according to their function. These proteins include the inter-α-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and β2GPI. Increased and decreased thiolester cleavage of α2M and Complement C3, respectively, was also detected. Although β2GPI is a novel biomarker for liver cirrhosis, it has already been observed in Hepatitis B virus (HBV)-mediated liver cancer (Drake et al., 2006, Mol Cell Proteomics). The decrease in Complement C3 has also been observed in HBV-mediated liver cancer (Steel et al., 2003, Proteomics, 3, 601). These novel proteins may also serve as biomarkers for hepatitis and HCC as well as drug targets for liver fibrosis, e.g. the novel biomarker, inter-α-trypsin inhibitor heavy chain H4, is cleaved by kallikrein a downstream activator of tissue-type plasminogen activator (tPA). tPA is known to be stimulated by drugs presently used in anti-fibrotic therapy (Nagaoka et al., 2003, Liver Int, 23, 476; Rimola, 2003, Am J Transplan, 5, 433).

<table>
<thead>
<tr>
<th>Patients with HCV-induced fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease</td>
</tr>
<tr>
<td>inter-α-trypsin inhibitor heavy chain H4 fragments</td>
</tr>
<tr>
<td>CD5L</td>
</tr>
<tr>
<td>complement factor H-related protein 1</td>
</tr>
<tr>
<td>β2GPI</td>
</tr>
<tr>
<td>Apo L1</td>
</tr>
<tr>
<td>thiolester cleavage of Complement C3.</td>
</tr>
<tr>
<td>thiolester cleavage of α2M</td>
</tr>
</tbody>
</table>

Example 5

[0123] The measurement of these novel proteins in serum will aid reliable diagnosis of both fibrosis and cirrhosis, which may eliminate the need for liver biopsy. These measurements can be achieved using an immunoassay with antibodies targeted against these proteins.

[0124] In the case of proteins that have altered cleavage, i.e. a2M, and inter-α-trypsin inhibitor heavy chain H4, the extent of cleavage can be established using N- and C-terminal binding antibodies. An antibody against the cleavage region can determine levels of an uncleaved biomarker. For a2M, two different antibodies can be used: 1) antibodies targeted to the N-terminal end of a2M before the thiolester cleavage site for the larger fragment; and 2) antibodies targeted to the C-terminal end of a2M after the cleavage site for the smaller fragment. Two different antibodies can be used in the case of inter-α-trypsin inhibitor heavy chain H4: 1) antibodies targeting the large 70 kDa chain; and 2) antibodies targeting the small 35 kDa chain. At present there appears to be no commercially available antibodies against the region of the thiolester site of a2M or the active peptide of inter-α-trypsin inhibitor heavy chain H4 where cleavage occurs. The antibody against the cleavage region can more reliably help to determine levels of the intact and cleaved biomarkers.

Example 6

[0125] A fibrosis scoring scale for each of the novel biomarkers can be formulated. The average concentration of these biomarkers in serum over the various stages of liver fibrosis is determined. A scale of 0 to 6 is presently used to assess liver fibrosis in the clinic where 0 represents no fibrosis, 1-5 represent the intermediate stages of fibrosis in increasing severity from mild to moderate/severe and 6 is cirrhosis (Ishak, 1995, J Hepatol, 22, 696). By determining the concentration ranges of the novel biomarkers across these seven stages, a similar scoring system of 0 to 6 can be assigned. The additive results from the scores of all the novel biomarkers give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.

Example 7

[0126] An Enzyme Linked Immunosorbent Assay (ELISA) is used to measure the novel fibrosis biomarkers. This is an assay performed in 96-well plate format. One option is to use the non-competitive one-site binding ELISA. In this assay,
known concentrations of antigen (in this example, the novel biomarkers and serum samples) are prepared in a bicarbonate buffer, added to the 96-well plate and incubated overnight at 4 °C. The wells are then washed three times with a solution of phosphate buffered saline (PBS) and Tween (PBS-T) followed by blocking with a PBS solution containing bovine serum albumin (BSA). After incubating at 37 °C for 1 hour, a primary antibody directed against the antigen (in this example, the biomarker of interest) is added, the plate incubated at 37 °C for 1 hour and then washed three times with PBS-T. A horseradish peroxidase (HRP)-conjugated secondary antibody, directed against the animal origin of the primary antibody, is then added, and the plate incubated at 37 °C for 1 hour followed by three washes with PBS-T. Finally, a peroxidase substrate such as 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) is added to each well and the absorbance read on a plate reader at 405 nm after 30 minutes.

Alternatively, a sandwich ELISA can be used. In this type of assay, one antibody is bound to the bottom of a plate well. The antigen, in this case the biomarker protein, is added and unbound products are removed by washing. A second, labeled antibody that binds to the antigen is then added. The amount of bound secondary antibody is quantified, usually colorimetrically. In addition to the novel biomarkers, the inventors propose that haptoglobin can be measured by ELISA. The levels of haptoglobin in serum, in conjunction with liver function tests (LFTs) determined by clinicians, will establish a more reliable score for liver fibrosis.

Table 1. Summary of selected differentially expressed proteins identified in serum samples of healthy controls vs. the different stages of hepatic scarring.\(^a\)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Protein Name</th>
<th>Mild</th>
<th>Moderate</th>
<th>Cirhosis</th>
<th>Protein Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasmin-associated</td>
<td>a2M</td>
<td>↑</td>
<td>→</td>
<td>↑→</td>
<td>Inhibits plasmin</td>
</tr>
<tr>
<td></td>
<td>ITIH4</td>
<td>-</td>
<td>-</td>
<td>↓←</td>
<td>Can be cleaved by kallikrein (leads to plasma activation)</td>
</tr>
<tr>
<td>Decreased because of compromise in hepatic synthetic function</td>
<td>Albumin</td>
<td>-</td>
<td>-</td>
<td>↓</td>
<td>Liver synthesized protein; most abundant protein in serum</td>
</tr>
<tr>
<td></td>
<td>Prealbumin (transthyrein)</td>
<td>-</td>
<td>-</td>
<td>↓</td>
<td>Liver synthesized protein; carries vitamin A</td>
</tr>
<tr>
<td></td>
<td>Complement C3, C4 and factor H-related protein 1</td>
<td>←</td>
<td>↓</td>
<td>↓←</td>
<td>Liver synthesized protein; involved in complement cascade</td>
</tr>
<tr>
<td>HGF-related</td>
<td>α1 antichymotrypsin</td>
<td>-</td>
<td>-</td>
<td>↓</td>
<td>HGF decreases α1 antichymotrypsin</td>
</tr>
<tr>
<td></td>
<td>Haptoglobin</td>
<td>↓</td>
<td>↓</td>
<td>↓←</td>
<td>HGF decreases haptoglobin synthesis</td>
</tr>
<tr>
<td>Lipid metabolism</td>
<td>Apo L1</td>
<td>-</td>
<td>-</td>
<td>←</td>
<td>Concentrations correlate with triglycerides and cholesterol</td>
</tr>
<tr>
<td></td>
<td>β2GP1</td>
<td>-</td>
<td>-</td>
<td></td>
<td>Binds to chylomicrons and HDLs</td>
</tr>
<tr>
<td></td>
<td>Panoxonase/arylesterase 1</td>
<td>-</td>
<td>-</td>
<td>↓</td>
<td>Degrades oxidized lipids in lipoproteins and cells</td>
</tr>
</tbody>
</table>
Claims

1. A method of detecting fibrosis, comprising:
   
   a) determining the level of apolipoprotein LI (Apo LI) in a biological sample obtained from a patient; and
   b) comparing said level of (a) to a control level of apolipoprotein LI (Apo LI) in order to determine a positive or negative diagnosis of said fibrosis.

2. A method for scaling the severity of fibrosis comprising:
   
   a) determining the level of apolipoprotein LI (Apo LI) in a biological sample obtained from a patient; and
   b) comparing said level of apolipoprotein LI (Apo LI) in the biological sample of the patient to a predetermined level of apolipoprotein LI (Apo LI) in a population of patients ranging from no fibrosis to cirrhosis.

3. A method of determining the prognosis of fibrosis, comprising:
   
   a) determining the level of apolipoprotein LI (Apo LI) in a biological sample obtained from a patient; and
   b) comparing said level to a control level of apolipoprotein LI (Apo LI) in order to determine a positive or negative diagnosis of said fibrosis.

4. The method of any one of claims 1 to 3, wherein the fibrosis includes differential regulation of apolipoprotein LI (Apo LI).

5. The method of any one of claims 1 to 4, wherein the biological sample is serum.

6. The method of any one of claims 1 to 5, wherein said fibrosis is hepatic fibrosis.
FIG. 1

Normal

Cirrhosis

FIG. 2

Normal

Cirrhosis

FIG. 3

Normal (cleaved)

Cirrhosis (uncleaved?)

70 kDa

35 kDa

FIG. 4

Normal

Cirrhosis
### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 2005/116901 A (UNIV ANGERS [FR]; CT HOSPITALIER UNIVERSITAIRE D [FR]; CALES PAUL [FR]) 8 December 2005 (2005-12-08) * the whole document *</td>
<td>1-6</td>
<td>GO1N</td>
</tr>
<tr>
<td>A</td>
<td>WO 2006/082522 A1 (ASSIST PUBL HOPITAUX DE PARIS [FR]; POYNARD THIERRY [FR]) 10 August 2006 (2006-08-10) * the whole document *</td>
<td>1-6</td>
<td>-/-</td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims

---

**Examiner:** Mauhin, Viviane

---

**CATEGORY OF CITED DOCUMENTS**

T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
A: technological background
O: non-written disclosure
P: intermediate document

**&**: member of the same patent family, corresponding document
### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 2005/116901 A (UNIV ANGERS [FR]; CT HOSPITALIER UNIVERSITAIRE D [FR]; CALES PAUL [FR]) 8 December 2005 (2005-12-08) * the whole document *</td>
<td>1-6</td>
<td></td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims

<table>
<thead>
<tr>
<th>Place of search</th>
<th>Date of completion of the search</th>
<th>Examiners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Munich</td>
<td>9 May 2012</td>
<td>Mauhin, Viviane</td>
</tr>
</tbody>
</table>
# Document Title:

**Title of the Document**

## Documents Considered to Be Relevant

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>Classification of the Application (IPC)</th>
<th>Technical Fields Searched (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>CARLO FABRIS ET AL: &quot;Low fibrosis progression of recurrent hepatitis C in apolipoprotein E e4 carriers: relationship with the blood lipid profile&quot;, LIVER INTERNATIONAL, vol. 25, no. 6, 1 December 2005 (2005-12-01), pages 1126-1135, XP55026666, ISSN: 1478-3223, DOI: 10.1111/j.1478-3231.2005.01156.x</td>
<td>1-6</td>
<td>----</td>
<td></td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims.

Examiner: Mauhin, Viviane

Date of completion of the search: 9 May 2012

Category of Cited Documents:

- X: particularly relevant if taken alone
- Y: particularly relevant if combined with another document of the same category
- A: technological background
- O: non-written disclosure
- P: intermediate document
- T: theory or principle underlying the invention
- E: earlier patent document, but published on, or after the filing date
- D: document cited in the application
- L: document cited for other reasons
- S: member of the same patent family, corresponding document


## DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
</table>

The present search report has been drawn up for all claims

<table>
<thead>
<tr>
<th>Place of search</th>
<th>Date of completion of the search</th>
<th>Examiner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Munich</td>
<td>9 May 2012</td>
<td>Mauhin, Viviane</td>
</tr>
</tbody>
</table>

**CATEGORY OF CITED DOCUMENTS**
- T: theory or principle underlying the invention
- E: earlier patent document, but published on, or after the filing date
- D: document cited in the application
- L: document cited for other reasons
- X: particularly relevant if taken alone
- Y: particularly relevant if combined with another document of the same category
- A: technological background
- O: non-written disclosure
- P: intermediate document
- S: member of the same patent family, corresponding document
ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

09-05-2012

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 2005116901 A</td>
<td>08-12-2005</td>
<td>CN 1985259 A</td>
<td>20-06-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1745403 A2</td>
<td>24-01-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2458384 A2</td>
<td>30-05-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2870348 A1</td>
<td>18-11-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2870349 A1</td>
<td>18-11-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009143993 A1</td>
<td>04-06-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2005116901 A2</td>
<td>08-12-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR P10606840 A2</td>
<td>09-03-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2596682 A1</td>
<td>10-08-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101175998 A</td>
<td>07-05-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2008529030 A</td>
<td>31-07-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MA 29282 B1</td>
<td>01-02-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2006173629 A1</td>
<td>03-08-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009111132 A1</td>
<td>30-04-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2006082522 A1</td>
<td>10-08-2006</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 60842980 B [0001]
- US 4366241 A [0064]
- US 4277437 A [0064]
- US 4275149 A [0064]
- US 3996345 A [0064]
- US 3993350 A [0064]
- US 3850752 A [0064]
- US 3817837 A [0064]
- WO 9316185 A [0104]
- US 5587458 A [0104]
- US 5571894 A [0104]

Non-patent literature cited in the description

- DRAKE et al. Mol Cell Proteomics, 2006 [0122]